Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 10:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 719 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Preliminary Efficacy Clear all
Completed Phase 2 Interventional Results available

Evaluate PKs and Efficacy Assessment of Palifermin in Patients With Sarcoma

NCT00267046
View directory record Official record
Conditions
Sarcoma, Oral Mucositis
Interventions
Palifermin, Placebo, Adriamycin (Doxorubicin), Ifosfamide, Vincristine, Cisplatin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
15 Years to 65 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 16, 2012 · Synced Oct 23, 2026, 10:14 AM EDT
Completed Not applicable Interventional Results available

Determining the Preliminary Efficacy of the Emergency Department Delirium Screening and Detection Program

NCT05638945
View directory record Official record
Conditions
Delirium
Interventions
ED Delirium Screening and Detection Program (ED-DDP)
Behavioral
Lead sponsor
Northwell Health
Other
Eligibility
65 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Manhasset, New York
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 23, 2026, 10:14 AM EDT
Recruiting Phase 1Phase 2 Interventional

Phase 1/2 Study of TU2218 Alone and in Combination With Checkpoint Inhibitors in Patients With Advanced Solid Tumors

NCT05204862
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
TU2218, Anti-PD-1 antibody
Drug
Lead sponsor
TiumBio Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 3, 2023 · Synced Oct 23, 2026, 10:14 AM EDT
Terminated Phase 2Phase 3 Interventional

Substance Use Disorder (SUD)-Associated Infections' Treatment With Dalbavancin ENabling OUtpatient Transition

NCT04847921
View directory record Official record
Conditions
Gram-Positive Bacterial Infections, Gram-Positive Bacteraemia, Substance Use Disorders, Intravenous Substance Abuse
Interventions
Dalbavancin
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 19, 2023 · Synced Oct 23, 2026, 10:14 AM EDT
Completed Phase 2 Interventional Results available

PERSEUS: Preliminary Efficacy and Safety of Cenicriviroc in Adult Participants With Primary Sclerosing Cholangitis

NCT02653625
View directory record Official record
Conditions
Primary Sclerosing Cholangitis
Interventions
Cenicriviroc 150 mg
Drug
Lead sponsor
Tobira Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
5
States / cities
La Jolla, California • Sacramento, California • San Francisco, California + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2018 · Synced Oct 23, 2026, 10:14 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies

NCT04644068
View directory record Official record
Conditions
Ovarian Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer, Additional Indications Below for Module 4 and 5, Non-small Cell Lung Cancer, Colorectal Cancer, Bladder Cancer, Gastric Cancer, Biliary Cancer, Cervical Cancer, Endometrial Cancer, Small Cell Lung Cancer Only in Module 5
Interventions
AZD5305, Paclitaxel, Carboplatin, T- Dxd, Dato-DXd, Camizestrant
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
702 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
5
States / cities
Boston, Massachusetts • New York, New York • Oklahoma City, Oklahoma + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 23, 2026, 10:14 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Safety and Efficacy Study of CC-122 in Combination With Nivolumab in Subjects With Unresectable Hepatocellular Carcinoma (HCC)

NCT02859324
View directory record Official record
Conditions
Carcinoma, Hepatocellular
Interventions
CC-122, Nivolumab
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
4
States / cities
Los Angeles, California • Gainesville, Florida • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated May 11, 2021 · Synced Oct 23, 2026, 10:14 AM EDT
Recruiting Phase 1Phase 2 Interventional

Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.

NCT07227012
View directory record Official record
Conditions
Carcinoma, Hepatocellular, Hepatocellular Cancer, Hepatocellular Carcinoma, Unresectable Hepatocellular Carcinoma, Liver Neoplasms, Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma
Interventions
PF-08634404, Ipilimumab
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
46
States / cities
Irvine, California • Los Angeles, California • Orange, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 23, 2026, 10:14 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Spinal Cord Injury Neuroprotection With Glyburide

NCT05426681
View directory record Official record
Conditions
Acute Spinal Cord Injury
Interventions
GlyBURIDE Oral Tablet
Drug
Lead sponsor
Francis Farhadi
Other
Eligibility
18 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2028
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 23, 2026, 10:14 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201 in NETs

NCT02592707
View directory record Official record
Conditions
Neuroendocrine Tumors
Interventions
Satoreotide tetraxetan, Amino acid solution, Antiemetic
Drug · Other
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 19, 2023 · Synced Oct 23, 2026, 10:14 AM EDT
Completed Phase 2 Interventional Results available

Preliminary Study of Piclozotan in Patients With Motor Complications Associated With Parkinson's Disease

NCT00623363
View directory record Official record
Conditions
Parkinson's Disease
Interventions
piclozotan, 0.9% sodium chloride (normal saline)
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
40 Years to 85 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
5
States / cities
Fountain Valley, California • Tampa, Florida • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2021 · Synced Oct 23, 2026, 10:14 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Study to Evaluate the Preliminary Safety, Efficacy, PK and PD of Bryostatin 1 in Patients With Alzheimer's Disease

NCT02221947
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Bryostatin 1, Placebo
Drug
Lead sponsor
Neurotrope Bioscience, Inc.
Industry
Eligibility
50 Years to 85 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Oct 23, 2026, 10:14 AM EDT
Recruiting Phase 1Phase 2 Interventional

Safety and Preliminary Efficacy of CTX112 in Adult Participants With Relapsed/Refractory Hematologic Autoimmune Disease

NCT07549698
View directory record Official record
Conditions
Warm Autoimmune Hemolytic Anemia (WAIHA), ITP - Immune Thrombocytopenia, Warm Autoimmune Hemolytic Anemia, Immune Thrombocytopenic Purpura
Interventions
CTX112
Biological
Lead sponsor
CRISPR Therapeutics AG
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
3
States / cities
Boston, Massachusetts • Rochester, Minnesota • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 23, 2026, 10:14 AM EDT
Terminated Phase 2 Interventional Results available

Assessment of the Safety, Tolerability and Efficacy of MEDI8968 in Subjects With Moderate to Severe Hidradenitis Suppurativa

NCT01838499
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
MEDI8968, Saline
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
27
States / cities
Phoenix, Arizona • Bakersfield, California • Fremont, California + 24 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2016 · Synced Oct 23, 2026, 10:14 AM EDT
Completed Phase 1 Interventional

Effect on QTc, Pharmacokinetics, Safety, and Preliminary Efficacy of Single-agent Palifosfamide-tris in Subjects With Advanced Solid Tumors

NCT01340547
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
palifosfamide-tris, Normal Saline
Drug
Lead sponsor
Alaunos Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
3
States / cities
Dallas, Texas • Houston, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 23, 2026, 10:14 AM EDT
Completed Phase 1 Interventional

A Study of NBF-006 in Non-Small Cell Lung, Pancreatic, or Colorectal Cancer

NCT03819387
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer
Interventions
NBF-006
Drug
Lead sponsor
Nitto BioPharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
9
States / cities
Beverly Hills, California • La Jolla, California • Tampa, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2024 · Synced Oct 23, 2026, 10:14 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Compassion Meditation for Cancer Survivor-Caregiver Dyads

NCT03459781
View directory record Official record
Conditions
Cancer Survivors, Informal Cancer Caregivers (Family and Friends of Cancer Survivors)
Interventions
Cognitively-Based Compassion Training, CHE (Cancer Health Education)
Behavioral
Lead sponsor
Thaddeus Pace
Other
Eligibility
21 Years and older
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 10, 2022 · Synced Oct 23, 2026, 10:14 AM EDT
Completed Phase 1 Interventional Results available

A Phase 1B Study to Investigate the Safety and Preliminary Efficacy for the Combination of Dasatinib Plus Nivolumab in Patients With Chronic Myeloid Leukemia

NCT02011945
View directory record Official record
Conditions
Chronic Myeloid Leukemia
Interventions
Dasatinib, Nivolumab
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
5
States / cities
Atlanta, Georgia • Boston, Massachusetts • Dallas, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2020 · Synced Oct 23, 2026, 10:14 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Active You: Feasibility of a Unique Physical Activity Program to Prevent Diabetes and Heart Disease

NCT04621045
View directory record Official record
Conditions
Cardiovascular Risk Factor, Prediabetes, Overweight and Obesity, Sedentary Behavior
Interventions
The Physical Activity for The Heart (PATH) intervention, Be Active Your Way Booklet
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
40 Years to 70 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
2
States / cities
Beaver Falls, Pennsylvania • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 7, 2022 · Synced Oct 23, 2026, 10:14 AM EDT
Completed Phase 1 Interventional

The Safety and Effectiveness of Clarithromycin Plus Zidovudine or Dideoxyinosine in the Treatment of Mycobacterium Avium Complex (MAC) Infections in Children With AIDS

NCT00000971
View directory record Official record
Conditions
Mycobacterium Avium-intracellulare Infection, HIV Infections
Interventions
Clarithromycin, Zidovudine, Didanosine
Drug
Lead sponsor
Abbott
Industry
Eligibility
3 Months to 18 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
Los Angeles, California • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 4, 2008 · Synced Oct 23, 2026, 10:14 AM EDT
Completed Phase 1Phase 2 Interventional

Research Study of Visilizumab for Treatment of Acute Graft Versus Host Disease

NCT00032292
View directory record Official record
Conditions
Graft vs Host Disease
Interventions
Visilizumab
Drug
Lead sponsor
Facet Biotech
Industry
Eligibility
Not listed
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
7
States / cities
Duarte, California • Stanford, California • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2012 · Synced Oct 23, 2026, 10:14 AM EDT
Completed Not applicable Interventional

Empowering Perinatal Adolescents Through Writing

NCT06771817
View directory record Official record
Conditions
Post-Traumatic Stress Disorder in Adolescence, PTSD - Post Traumatic Stress Disorder, PTSD and Trauma-related Symptoms, Pregnancy and PTSD
Interventions
Written Exposure Therapy
Behavioral
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
15 Years to 24 Years · Female only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 23, 2026, 10:14 AM EDT
Terminated Phase 1 Interventional Results available

Trial to Evaluate the Safety and Pharmacokinetics of HMPL-689 in Patients With Lymphomas

NCT03786926
View directory record Official record
Conditions
Lymphoma
Interventions
HMPL-689
Drug
Lead sponsor
Hutchmed
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
10
States / cities
Anaheim, California • Oxnard, California • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2025 · Synced Oct 23, 2026, 10:14 AM EDT
Completed Phase 2 Interventional

To Evaluate the Preliminary Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CC-11050 in Subjects With Discoid Lupus Erythematosus and Subacute Cutaneous Lupus Erythematosus

NCT01300208
View directory record Official record
Conditions
Cutaneous Lupus Erythematosus
Interventions
CC-11050, Placebo
Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
19
States / cities
Rogers, Arkansas • Los Angeles, California • San Diego, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2020 · Synced Oct 23, 2026, 10:14 AM EDT